Hims & Hers Stock Rebounds 33% from Lows on Wegovy Deal With Novo Nordisk
Hims & Hers Health stock has surged 26% following a strategic partnership with Novo Nordisk for the weight-loss drug Wegovy. The digital health company is capitalizing on rising demand by offering a bundled package starting at $599, fueling investor optimism.
The stock’s near-triple performance over the past year reflects growing confidence in telehealth solutions. Upcoming Q1 earnings are anticipated to shed light on whether this momentum can sustain the early 2025 technical rebound.